The FDA decision on the Intravenous Push mode of administration of Theratechnologies Inc.’s (THTX) antiretroviral medication Trogarzo is expected on October 3.Trogarzo, indicated for adult patients living with HIV who have limited treatment options, is administered as an intravenous (IV) infusion over 15 to 30 minutes, every 2 weeks. This drug is used in combination with other antiretroviral medications.According to the company, the IV Push mode of administration is very convenient and also offers patients a rapid infusion time and requires only two quick infusions per month.For the six-month period ended May 31, 2022, Trogarzo net sales improved to $14.71 million from $14.2 million in the same period in 2021.THTX closed Thursday’s (Sep.29,2022) trading at $2.30, down 2.13%.